Phase 3 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent before any trial procedures begin
• Adults aged 18 to 75 years (any gender)
• People with a tissue-confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat), classified under the latest WHO guidelines as keratinizing, non-keratinizing differentiated, or undifferentiated type
• People whose cancer is locally advanced (stages cT1–4, N0–3, M0 under the AJCC 9th Edition staging system — meaning the cancer has not spread to distant parts of the body) (confirm with trial site)
• People who have not previously received systemic anti-cancer treatment (such as chemotherapy) for this locally advanced disease
• People who are generally well enough to carry out light activity and care for themselves, as assessed by a standard medical scale called ECOG performance status 0–1
• People whose blood counts meet minimum levels: enough white blood cells (neutrophils), platelets, and red blood cells (haemoglobin) as measured by blood tests
• People whose liver enzyme levels (AST and ALT) are within an acceptable range based on blood tests
• People whose kidney function is adequate, based on blood creatinine levels and a calculated kidney clearance rate
• People with no clinically significant abnormalities in blood clotting tests, as judged by the investigating doctor
• People with no clinically significant abnormalities in heart enzyme (myocardial enzyme) blood tests, as judged by the investigating doctor

Who may not be able to join:

• People whose cancer has spread to distant parts of the body (called M1 or distant metastasis)
• People with squamous cell carcinoma of the head and neck that did not start in the nasopharynx
• People with a nasopharyngeal cancer type other than keratinizing or non-keratinizing carcinoma (confirm with trial site, as this interacts with the inclusion criteria above)
• People who are currently taking part in another interventional clinical trial
• People for whom radiotherapy is medically unsuitable or contraindicated
• People with untreated, active hepatitis B infection (defined as a positive hepatitis B surface antigen with a viral load above the normal limit at the trial site's laboratory) — note: people with hepatitis B whose viral load is below a certain level and who receive anti-hepatitis B treatment throughout the study may still be considered eligible (confirm with trial site)
• People with active hepatitis C infection (confirmed by a positive antibody test and detectable hepatitis C virus in the blood)
• People who are pregnant
• People with serious or uncontrolled heart conditions, including significant abnormal heart rhythms or electrical conduction problems, unstable chest pain (angina), heart failure (NYHA class 2 or above), or a heart attack, stroke, or related event within the past 6 months
• People with a history of lung inflammation (non-infectious pneumonitis) requiring steroid treatment within the past year, or who currently have active interstitial lung disease
• People with active tuberculosis of the lungs
• People with an active infection currently requiring systemic treatment (such as intravenous antibiotics)
• People with active diverticulitis, an abscess in the abdomen, or a bowel obstruction
• People with serious liver disease, including severe cirrhosis or active hepatitis
• People with a mental health condition that would prevent them from cooperating with treatment
• People with any other medical history, ongoing condition, or abnormal test result that the investigating doctor believes could interfere with the study or make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.